Recent research in triple-negative breast cancer (TNBC) has shown that PRMT1-induced methylation of PKM2, together with PHGDH and PFKFB3, shifts glucose metabolism to serine synthesis, increasing fatty acid production and chemoresistance, underscoring the crucial role of PKM2 modifications in tumor drug resistance [40]. The gene discussed is PRMT1; the disease is neoplasm.